Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data

Pharmacology and Therapeutics

Volumn 73, Issue 2, 1997, Pages 147-171

  Iwatsubo, Takafumi ^a   Hirota, Noriko ^b   Ooie, Tsuyoshi ^b   Suzuki, Hiroshi ^b   Shimada, Noriaki ^c   Chiba, Kan ^d   Ishizaki, Takashi ^d   Green, Carol E ^e   Tyson, Charles A ^e   Sugiyama, Yuichi ^a,b  

^a ASTELLAS PHARMA INC   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c DAIICHI PURE CHEMICALS CO LTD   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^e SRI INTERNATIONAL   (United States)

Author keywords

clearance concept; drug metabolism; first pass metabolism; in vitro in vivo prediction; nonlinear pharmacokinetics; physiologically based pharmacokinetics

Indexed keywords

2,8 DIMETHYL 3 METHYLENE 1 OXA 8 AZASPIRO[4.5]DECANE; ALPRAZOLAM; CYTOCHROME P450; DIAZEPAM; DOFETILIDE; IMIPRAMINE; LIDOCAINE; LOXTIDINE; METOPROLOL; MEXILETINE; PHENACETIN; QUINIDINE; THEOPHYLLINE; TOLBUTAMIDE; UNCLASSIFIED DRUG; VERAPAMIL; WARFARIN;

DRUG CLEARANCE; DRUG METABOLISM; DRUG TRANSPORT; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTRAVENOUS DRUG ADMINISTRATION; LIVER METABOLISM; LIVER MICROSOME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; THEORETICAL STUDY;

EID: 0030937636     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(96)00184-2     Document Type: Review

References (84)

1. Ahmad, A. B., Bennett, P. N. and Rowland, M. (1983) Models of hepatic drug clearance: discrimination between the "well-stirred" and "parallel-tube" models. J. Pharm. Pharmacol. 35: 219-224.
2. Bargetzi, M. J., Aoyama, T., Gonzalez, F. J. and Meyer, U. A. (1989) Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin. Pharmacol. Ther. 46: 521-527.
3. Bass, L. and Keidmg, S. (1988) Physiologically based models and strategic experiments in hepatic pharmacology. Biochem. Pharmacol. 37: 1425-1431.
4. Bass, L., Robinson, P. and Bracken, A. J. (1978) Hepatic elimination of flowing substrates: the distributed model. J. Theor. Biol. 72: 161-184.
5. Bayliss, M. K., Bell, J. A., Jenner, W. N. and Wilson, K. (1990) Prediction of intrinsic clearance of loxtidine from kinetic studies in rat, dog and human hepatocytes. Biochem. Soc. Trans. 18: 1198-1199.
6. Beckert, A. H. and Chidomere, E. C. (1977) The distribution, metabolism and excretion of mexiletine in man. Postgrad. Med. J. 53 (Suppl. 1): 60-66.
7. Bischoff, K. B., Dedrick, R. L., Zaharko, D. S. and Longstreth, J. A. (1971) Methotrexate pharmacokinetics. J. Pharm. Sci. 60: 1128-1133.
8. Boxenbaum, H. (1980) Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance extrapolation of data to benzodiazepines and phenytoin. J. Pharmacokinet. Biopharm. 8: 165-176.
9. Boxenbaum, H. (1982) Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J. Pharmacokinet. Biopharm. 10: 201-227.
10. Broly, F., Libersa, C. and Lhermitte, M. (1990) Mexiletine metabolism in vitro by human liver. Drug Metab. Dispos. 18: 362-368.
11. Chan, E., Pegg, M., Mackay, A. S., Cole, R. B. and Rowland, M. (1984) Stereochemical aspects of warfarin in patients receiving chronic therapy. Br. J. Clin. Pharmacol. 19: 571.
12. Chiba, K., Saitoh, A., Koyama, E., Tani, M., Hayashi, M. and Ishizaki, T. (1994) The role of mephenytoin 4′-hydroxylase in imipramine metabolism by human liver microsomes: a two enzyme kinetic analysis of N-demethylation and 2-hydroxylation. Br. J. Clin. Pharmacol. 37: 237-242.
13. Chiba, M., Hensleigh, M., Nishime, J. A., Balani, S. K. and Lin, J. H. (1996) Role of cytochrome P4503A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 24: 307-314.
14. Ciraulo, D. A., Barnhill, J. G. and Jaffe, J. H. (1988) Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. Clin. Pharmacol. Ther. 43: 509-518.
15. Dedrick, R. L. (1973) Animal scale-up. J. Pharmacokinet. Biopharm. 1: 435-461.
16. Dedrick, R. L., Forester, D. D., Cannon, J. N., ElDareen, S. M. and Mellett, L. B. (1973) Pharmacokinetics of 1-β-D-arabinofuranosylcytosine (Ara-C) deamination in several species. Biochem. Pharmacol. 22: 2405-2417.
17. 14C-alprazolam, a new anxiolytic-antidepressant, in man. Pharmacologist 22: 279.
18. Grant, M. H., Burke, M. D., Hawksworth, G. M., Duthie, S. J., Engeset, J. and Petrie, J. C. (1987) Human adult hepatocytes in primary monolayer culture. Maintenance of mixed function oxidase and conjugation pathways of drug metabolism. Biochem. Pharmacol. 36: 2311-2316.
19. Gross, A. S., Heuer, B. and Eichelbaum, M. (1988) Stereoselective protein binding of verapamil enantiomers. Biochem. Pharmacol. 37: 4623-4627.
20. Hardy, B. G. and Schentag, J. (1988) Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance. Int. J. Clin. Pharmacol. Ther. Toxicol. 26: 388-391.
21. Hebert, M. F., Roberts, J. P., Prueksaritanont, T. and Benet, L. Z. (1992) Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther. 52: 453-457.
22. Hoener, B.-A. (1994) Predicting the hepatic clearance of xenobiotics in humans from in vitro data. Biopharm. Drug Dispos. 15: 295-304.
23. Horai, Y., Nakano, M., Ishizaki, T., Ishikawa, K., Zhou, H. H., Zhou, B. J., Liao, C. L. and Zhang, L. M. (1989) Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin. Pharmacol. Ther. 46: 198-207.
24. Houston, J. B. (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47: 1469-1479.
25. Imaoka, S., Enomoto, K., Oda, Y., Asada, A., Fujimori, M., Shimada, T., Fujita, S., Guengerich, F. P. and Funae, Y. (1990) Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s. J. Pharmacol. Exp. Ther. 255: 1385-1391.
26. Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H. and Sugiyama, Y. (1996) Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm. Drug Dispos. 17: 273-310.
27. Jacolot, F., Simon, I., Dreano, Y., Beaune, P., Riche, C. and Berthou, F. (1991) Identification of cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol. 41: 1911-1919.
28. Johansson, K. A., Appelgern, C., Borg, K. O. and Elofsson, R. (1974) Binding of two adrenergic beta-receptor antagonists, alprenolol and H 93/26, to human serum proteins. Acta Pharm. Suec. 11: 333-346.
29. Kato, R. and Yamazoe, Y. (1994) The importance of substrate concentration in determining cytochromes P450 therapeutically relevant in vivo. Pharmacogenetics 4: 359-362.
30. Keenaghan, J. B. and Boyes, R. N. (1972) The tissue distribution, metabolism and excretion of lidocaine in rats, guinea pigs, dogs and man. J. Pharmacol. Exp. Ther. 180: 454-463.
31. Kirn, M., Shen, D. D., Eddy, A. C. and Nelson, W. L. (1992) Inhibition of the enantioselective oxidative metabolism of metoprolol by verapamil in human liver microsomes. Drug Metab. Dispos. 21: 309-317.
32. Klotz, U., Antonin, K. H. and Bieck, P. R. (1976) Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. J. Pharmacol. Exp. Ther. 199: 67-73.
33. Kroemer, H. K., Echizen, H., Heidemann, H. and Eichelbaum, M. (1992) Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. J. Pharmacol. Exp. Ther. 260: 1052-1057.
34. Lin, J. H. (1995) Species similarities and differences in pharmacokinetics. Drug Metab. Dispos. 23: 1008-1021.
35. Lin, J. H., Hayashi, M., Awazu, S. and Hanano, M. (1978) Correlation between in vitro and in vivo drug metabolism rate: oxidation of ethoxybenzamide in rat. J. Pharmacokinet. Biopharm. 6: 327-337.
36. Lin, J. H., Sugiyama, Y., Awazu, S. and Hanano, M. (1980) Kinetic studies on the deethylation of ethoxybenzamide: a comparative study with isolated hepatocytes and liver microsomes of rat. Biochem. Pharmacol. 29: 2825-2830.
37. Mikus, G., Ha, H. R., Vozeh, S., Zekom, F., Follath, F. and Eichelbaum, M. (1986) Pharmacokinetics and metabolism of quinidine in extensive and poor metabolizers of sparteine. Eur. J. Clin. Pharmacol. 31: 69-72.
38. Miller, A. K., Adir, J. and Vestral, R. E. (1990) Excretion of tolbutamide metabolites in young and old subjects. Eur. J. Clin. Pharmacol. 38: 523-524.
39. Mitenko, P. A. and Ogillvie, R. I. (1973) Pharmacokinetics of intravenous theophylline. Clin. Pharmacol. Ther. 14: 509-513.
40. Monks, T. J., Smith, R. L. and Caldwell, J. (1979) A metabolic and pharmacokinetic comparison of theophylline and aminophylline (theophylline ethylenediamine). J. Pharm. Pharmacol. 163: 351-362.
41. Montandon, B., Roberts, R. J. and Fischer, L. J. (1975) Computer simulation of sulfobromophthalein kinetics in the rat using flow-limited models with extrapolation to man. J. Pharmacokinet. Biopharm. 3: 277-290.
42. Oberle, R. L., Chen, T.-S-, Lloyd, C., Barnett, J. L., Owyang, C., Meyer, J. and Amidon, G. L. (1990) The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids. Gastroenterology 99: 1275-1282.
43. Otton, S. V., Brinn, R. U. and Gram, L. F. (1987) In vitro evidence against the oxidation of quinidine by the sparteine/ debrisoquine monooxygenase of human liver. Drug Metab. Dispos. 16: 15-17.
44. Pang, K. S. and Rowland, M. (1977a) Hepatic clearance of drugs: I. Theoretical considerations of a "well-stirred" model and a "parallel-tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J. Pharmacokinet. Biopharm. 5: 625-653.
45. Pang, K. S. and Rowland, M. (1977b) Hepatic clearance of drugs. II. Experimental evidence for acceptance of the "well-stirred" model over the "parallel-tube" model using lidocaine in the perfused rat liver in situ preparation. J. Pharmacokinet. Biopharm. 5: 655-680.
46. Pentikainen, P. J., Halmen, M. O. and Helm, M. J. (1983) Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction. Eur. J. Clin. Pharmacol. 25: 773-777.
47. Piafsky, K., Sitar, D. S., Rangno, R. E. and Ogillvie, R. I. (1977) Theophylline disposition in patients with hepatic cirrhosis. N. Engl. J. Med. 296: 1495-1497.
48. Prescott, L. F., Clements, J. A. and Pottage, A. (1977) Absorption, distribution and elimination of mexiletine. Postgrad. Med. J. 53 (Suppl. 1): 50-55.
49. Quarterman, C. P., Kendall, M. J. and Jack, D. B. (1981) The effect of age on the pharmacokinetics of metoprolol and its metabolites. Br. J. Clin. Pharmacol. 11: 287-294.
50. Raaflaub, J. and Dubach, U. C. (1975) On the pharmacokinetics of phenacetin in man. Eur. J. Clin. Pharmacol. 8: 261-265.
51. Rane, A., Wilkinson, G. R. and Shand, D. G. (1977) Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J. Pharmacol. Exp. Ther. 200: 420-424.
52. Regärdh, C. G., Borg, K. O., Johansson, R. and Palmer, L. (1974) Pharmacokinetics studies on the selective b1-receptor antagonist metoprolol in man. J. Pharmacokinet. Biopharm. 2: 347-364.
53. Remmel, R. P., Copa, A. K. and Angaran, D. M. (1991) The effects of hemodilution pH and protamine on lidocaine plasma protein binding and red blood-cell uptake in vitto. Pharm. Res. 8: 127-130.
54. Renaud, J.-P., Cullin, C., Pompon, D., Beaune, P. and Mansuy, D. (1990) Expression of human liver cytochrome P450IIIA4 in yeast: a functional model for the hepatic enzyme. Eur. J. Biochem. 194: 889-896.
55. Rettie, A. E., Eddy, A. C., Heimark, L. D., Gibaldi, M. and Trager, W. F. (1988) Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab. Dispos. 17: 265-270.
56. Richard, B., Fabre, G., Sousa, G. D., Fabre, I., Rhamani, R. and Cano, J. P. (1991) Interspecies variability in mitoxantrone metabolism using primary cultures of hepatocytes isolated from rat, rabbit and human. Biochem. Pharmacol. 41: 255-262.
57. Roberts, M. S. and Rowland, M. (1986a) A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. J. Pharmacokinet. Biopharm. 14: 227-260.
58. Roberts, M. S. and Rowland, M. (1986b) Correlation between in vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model. J. Pharm. Pharmacol. 38: 177-181.
59. Roberts, M. S., Donaldson, J. D. and Rowland, M. (1988) Models of hepatic elimination: comparison of stochastic models to describe residence time distributions and to predict the influence of drug distribution, enzyme heterogeneity, and systemic recycling on hepatic elimination. J. Pharmacokinet. Biopharm. 16: 41-83.
60. Robson, R. A., Matthews, A. P., Miners, J. O., McManus, M. E., Meyer, U. A., Hall, P. M. and Birkett, D. J. (1987) Characterisation of theophylline metabolism in human liver microsomes. Br. J. Clin. Pharmacol. 24: 293-300.
61. Rowland, M., Benet, L. Z. and Graham, G. (1973) Clearance concepts in pharmacokinetics. J. Pharmacokinet. Biopharm. 1: 123-136.
62. Sawada, Y., Hanano, M., Sugiyama, Y. and Iga, T. (1984) Prediction of the disposition of β-lactam antibiotics in human from pharmacokinetic parameters in animals. J. Pharmacokinet. Biopharm. 12: 241-261.
63. Schaaf, L. J., Cambell, S. C., Mayersohn, M. B., Vagedes, T. and Perrier, D. G. (1987) Influence of smoking and gender on the disposition kinetics of metoprolol. Eur. J. Clin. Pharmacol. 33: 355-361.
64. Schomerus, M., Spiegelhalder, B., Stieren, B. and Eichelbaum, M. (1976) Physiological disposition of verapamil in man. Cardiovasc. Res. 10: 605-612.
65. Seddon, T., Michelle, I. and Chenery, R. J. (1989) Comparative drug metabolism of diazepam in hepatocytes isolated from man, rat, monkey and dog. Biochem. Pharmacol. 38: 1657-1665.
66. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, F. P. (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270: 414-422.
67. Smith, D. A., Rasmussen, H. S., Stopher, D. A. and Walker, D. K. (1992) Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. Xenobiotica 22: 709-719.
68. Smith, R. B., Kroboth, P. D., Vanderlugt, J. T., Phillips, J. P. and Juhl, R. P. (1984) Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology 84: 452-456.
69. Smith, R. L. and Timbrell, J. A. (1974) Factors affecting the metabolism of phenacetin I. Influence of dose, chronic dosage, route of administration and species on the metabolism of [1-16C-acetyl]phenacetin. Xenobiotica 4: 489-501.
70. Sugiyama, Y., Sawada, Y., Iga, T. and Hanano, M. (1988) Xenobiotic metabolism and disposition. In: Proceedings of the 2nd International ISSX Meeting, Kobe, May 16-20, pp. 225-235, Kato, R., Estabrook, R. W. and Cayen, M. N. (eds.) Taylor & Francis, London.
71. Suzuki, H., Iwatsubo, T. and Sugiyama, Y. (1995) Applications and prospects for physiologically based pharmacokinetic (PB-PK) models involving pharmaceutical agents. Toxicol. Lett. 82/ 83: 349-355.
72. Suzuki, T., Isozaki, S., Ishida, R., Saitoh, Y. and Nakagawa, F. (1974) Drug absorption and metabolism studies by use of portal vein infusion in the rat. II: Influence of dose and infusion rate on the bioavailability of propranolol. Chem. Pharm. Bull. 22: 1639-1645.
73. Thummel, K. E, Shen, D. D., Podoll, T., Kunze, K. L., Trager, W. F., Hartwell, P., Raisvs, V. A., Marsh, C. L., McVicar, J. P., Barr, D. M., Perkins, J. D. and Carithers, R. L., Jr. (1994) Use of midazolam as a human cytochrome P4503A probe: I. In vitro-in vino correlations in liver transplant patients. J. Pharmacol. Exp. Ther. 271: 549-556.
74. Toon, S., Low, L. K., Gibaldi, M., Trager, W. F., O'Reilly, R. A., Motley, C. H. and Goulart, D. A. (1986) The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin. Pharmacol. Ther. 39: 15-24.
75. Turgeon, J., Grech-Belanger, O. and Gilbert, M. (1987) Erythrocyte and serum distribution of mexiletine in man. Biopharm. Drug Dispos. 8: 571-576.
76. Vesell, E. S., Passananti, G. T., Glenwright, P. A. and Dovrchik, B. H. (1975) Studies on the disposition of antipyrine, aminopyrine and phenacetin using plasma, saliva and urine. Clin. Pharmacol. Ther. 18: 259-272.
77. von Moltke, L., Greenblatt, D. J., Harmatz, J. S. and Shader, R. I. (1993) Alprazolam metabolism in vitro: studies of human, monkey, mouse and rat liver microsomes. Pharmacology 47: 268-276.
78. Wilkinson, G. R. (1987) Clearance approaches in pharmacology. Pharmacol. Rev. 39: 1-47.
79. Wilkinson, G. R. and Shand, D. G. (1975) A physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther. 18: 377-390.
80. Williams, R. L., Blaschke, T. F., Meffin, P. J., Melmon, K. L. and Rowland, M. (1976) Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide. Clin. Pharmacol. Ther. 21: 301-309.
81. Wing, L. M. H., Miners, J. O., Birkett, D. J., Phill, D., Foenannder, T., Lillywhite, K. and Wanwimolruk, S. (1984) Lidocaine disposition - Sex difference and effects of cimetidine. Clin. Pharmacol. Ther. 35: 695-701.
82. Winkler, K., Keiding, S. and Tygstrup, N. (1973) The liver. In: Quantitative Aspects of Structure and Function, pp. 144-155, Paumgartner, G. and Preisig, R. (eds.) S. Karger, Basel.
83. Yasumori, T., Nagata, K., Yang, S. K., Chen, L. S., Murayama, N., Yamazoe, Y. and Kato, R. (1993) Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmacogenetics 3: 291-301.
84. Yu, V. C., Lamirande, E. D., Horning, M. G. and Pang, K. S. (1982) Dose-dependent kinetics of quinidine in the perfused rat liver preparation. Kinetics of formation of active metabolites. Drug Metab. Dispos. 10: 568-572.